Dry Eye Clinical Trial
Official title:
The Effect of Computer Eyewear on Viewing Comfort and Performance in Office Work
Verified date | October 2016 |
Source | Pacific University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
The proposed study aims to test if Gunnar computer glasses provide any advantages, in
comparison to no glasses, on the following aspects in computer-related office work:
- Any enhancement on visual performance of basic visual function, including visual
acuity, contrast sensitivity, color discrimination, etc.
- Any enhancement on visual performance of typical office work, including reading,
word-spelling check, number searching, or target identification.
- Any benefit in objective viewing comfort measured with viewing distance, blink
frequency, post-viewing pupil size.
- Any benefit in subjective viewing comfort reflected on the questionnaire of viewing
symptom survey.
- Any benefit in viewing comfort and visual performance with increased environmental
ventilation or under strong glare.
- Any benefit in life quality from daily wearing (e.g., better comfort or sleep quality).
Status | Terminated |
Enrollment | 34 |
Est. completion date | September 2013 |
Est. primary completion date | September 2013 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 42 Years |
Eligibility |
Inclusion Criteria: - Subjects must be in the age between 18 to 42 years old. - Subjects must have normal color vision (be able to identify the numbers in the color blind test. - Subjects' near and far visual acuity with the better eye needs to be 20/25 (measured with a vision chart or better). Subjects can wear contact lenses (but not glasses) if usually wear them while working on computers. - Subjects must routinely work on a computer or digital display for average 4 hours or more each day. - Subjects can communicate in English fluently, and are used to read English documents on computer. - Subjects with existing conditions of dry eye or eye strain will be recorded and serve as a covariate to determine the experimental effect. - Subjects must have valid tax number or social security number to receive monetary compensation. Exclusion Criteria: - The difference on the prescription for both eyes is equal to or larger than 2 Diopters. - Subjects have cataract or have had cataract surgery. - Subjects are sensitive to lights (photosensitivity). - Subjects have prior incidents or are known to have claustrophobia. - Subjects have been diagnosed with oculomotor diseases or central nervous system diseases, or with developmental, neurological, or psychiatric disorders (e.g., attention deficit hyperactivity disorder, autism, mental retardation). |
Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label
Country | Name | City | State |
---|---|---|---|
United States | Vision Performance Institute, Pacific University | Forest Grove | Oregon |
Lead Sponsor | Collaborator |
---|---|
Pacific University | Gunnar Optiks |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Subjective rating of Gunnar computer glasses preference | At the end of the study, subjects were asked to rate their satisfaction level of using the Gunnar OTC computer glasses on improving viewing comfort task performance. | Measurement was taken at the end of the study for each subject, up to 16 days. Data collection and preliminary analysis has been completed. | No |
Secondary | Viewing discomfort | Subjects subjective rating of viewing comfort with the assigned treatment on the Viewing Symptom Survey. They will rate their discomfort sensation on a 5-point Likert scale for symptoms including: dry or watery eyes, tired eyes, irritated eyes, ache in or behind the eyes, sensation of eye-pulling, sensation of eye-burning, sensitive to lights, blurred vision, double vision, difficulty in adjusting eye focus, difficulty in seeing things with bright light, difficulty in seeing things with normal light, distortion in object shapes, distortion in object colors. | Subjective ratings of discomfort were assessed after each condition on the second and third visits, up to 16 days. Data collection and preliminary analysis has been completed. | No |
Secondary | Visual acuity | subject's ability in identifying high- and low-contrast objects | Performance was measured in each condition on the second and third visits, up to 16 days. Data collection and preliminary analysis has been completed. | No |
Secondary | Color perception | subject's ability to identify the number of shades of a color | Performance was measured in each condition on the second and third visits, up to 16 days. Data collection and preliminary analysis has been completed. | No |
Secondary | Reading | subject's reading speed and speed and accuracy in spelling check | Performance was measured in each condition on the second and third visits, up to 16 days. Data collection and preliminary analysis has been completed. | No |
Secondary | Dry eye measurements | Dry eye condition was measured with one subjective measurement on a standardized survey (Ocular Surface Disease Index , OSDI) and four objective measurements: (1)Tear Break-Up Time (TBUT), (2) tear osmolarity with The TearLab Osmolarity System), (3) corneal integrity with Lissamine green, and (4) real-time blink-contingent visual acuity. | Measurement was taken at baseline and after each condition on the second and third visits, up to 16 days. Data collection and preliminary analysis has been completed. | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05027087 -
The Effect of a Novel Blueberry Supplement on Dry Eye Disease
|
Phase 3 | |
Completed |
NCT06159569 -
Performance and Tolerability of the Medical Device LACRIACT
|
N/A | |
Completed |
NCT05102409 -
An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease
|
Phase 2 | |
Completed |
NCT04081610 -
Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution
|
Phase 1 | |
Completed |
NCT05062564 -
Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye
|
N/A | |
Completed |
NCT05825599 -
PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms
|
N/A | |
Completed |
NCT03418727 -
Dry Eye Disease Study With Brimonidine
|
Phase 2 | |
Active, not recruiting |
NCT04425551 -
Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction
|
N/A | |
Recruiting |
NCT04527887 -
Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED)
|
Phase 4 | |
Not yet recruiting |
NCT06379685 -
Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface.
|
Phase 1 | |
Active, not recruiting |
NCT05618730 -
Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B
|
Phase 1 | |
Completed |
NCT04553432 -
Dry Eye OmniLenz Application of Omnigen Research Study
|
Phase 4 | |
Recruiting |
NCT04109170 -
Dry Eye Evaluation System Based on Bioinformatics
|
||
Completed |
NCT04105842 -
Refitting Daily Disposable Contact Lens Wearers With Dry Eye Disease With A Different Daily Disposable Lens Type
|
N/A | |
Completed |
NCT05505292 -
Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers
|
Phase 4 | |
Completed |
NCT04668131 -
Study on Curative Effect and Mechanism of Acupuncture on Neuropathic Pain in Dry Eye Disease
|
N/A | |
Completed |
NCT06176651 -
Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers
|
Phase 4 | |
Not yet recruiting |
NCT02218827 -
Topical Steroid Treatment For Dry Eye
|
N/A | |
Completed |
NCT02235259 -
Efficacy and Safety of XG-104 for the Treatment of Dry Eye
|
Phase 2 | |
Completed |
NCT01959854 -
Efficacy of Topical 0.2% Xanthan Gum in Patients With Dry Eye
|
N/A |